汉森制药(002412) - 2014 Q3 - 季度财报

Financial Performance - Operating revenue for the reporting period was CNY 168,062,633.76, an increase of 24.92% year-on-year[4]. - Net profit attributable to shareholders was CNY 24,075,040.48, reflecting a growth of 5.09% compared to the same period last year[4]. - The net profit after deducting non-recurring gains and losses was CNY 23,624,618.60, up by 4.19% year-on-year[4]. - The weighted average return on net assets was 2.25%, an increase of 0.02% compared to the previous year[4]. - The increase in net profit is attributed to the continuous growth in operating income[20]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,321,624,898.51, a decrease of 0.04% compared to the end of the previous year[4]. - Accounts receivable increased by CNY 59,104,378.24, a growth of 69.35%, mainly due to sales prepayments[12]. - Short-term borrowings increased by CNY 40,000,000.00, a 100% increase, primarily due to a bank loan taken by Yunnan Yongzitang Pharmaceutical Co., Ltd.[12]. - Long-term borrowings decreased by CNY 40 million, a decline of 100%, primarily due to the repayment of CNY 40 million by Yunnan Yongzitang Pharmaceutical Co., Ltd.[13]. - Deferred income tax liabilities decreased by CNY 23,306.67, a decline of 100%, mainly due to the reduction in inventory at the end of the period from internal sales of products.[13]. Cash Flow - The company reported a net cash flow from operating activities of CNY 57,016,330.34, a decrease of 1.69% year-to-date[4]. - Net cash flow from investment activities decreased by CNY 428,460,140.77, a decline of 114.83%, mainly due to a reduction in cash received from investment recoveries.[15]. - Net cash flow from financing activities decreased by CNY 79,052,504.09, a decline of 7907.71%, primarily due to cash dividends of CNY 74 million paid during the period.[15]. Operating Costs and Expenses - Operating costs increased by CNY 43,822,717.31, a growth of 41.05%, primarily due to an increase in operating income of CNY 91,546,225.35 compared to the same period last year.[14]. - Management expenses increased by CNY 13,007,127.60, a growth of 37.97%, mainly due to the increase in management expenses of CNY 11,118,107.60 from the consolidation of Yunnan Yongzitang Pharmaceutical Co., Ltd.[14]. - Financial expenses increased by CNY 9,618,755.42, a growth of 94.18%, primarily due to reduced interest income from decreased bank deposits and increased financial expenses from the consolidation of Yunnan Yongzitang Pharmaceutical Co., Ltd.[14]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 13,562[8]. - The largest shareholder, Xinjiang Hansen Equity Investment Management Partnership, held 51.37% of the shares[8]. - The company has committed to ensuring that its major shareholders do not engage in competitive business activities that may harm the interests of minority shareholders.[19]. Future Projections - The net profit attributable to shareholders for 2014 is expected to be between 116.37 million and 144.08 million RMB, representing a growth of 5.00% to 30.00% compared to 110.83 million RMB in 2013[20]. Investments - The company approved the use of CNY 49.28 million of raised funds for GMP renovation of the old workshop, which is currently under construction.[16]. - The company also approved the investment of CNY 62.5372 million of raised funds to establish a wholly-owned subsidiary, Henson Health Industry (Hunan) Co., Ltd., which has completed its business registration.[16]. - The company does not have any securities investments during the reporting period[21]. - The company did not hold any equity in other listed companies during the reporting period[21].